Author(s): World Health Organization
Revised drug resistance surveillance guidelines will become available later this year. In the interim, this document has been drafted to provide guidance on the areas that will be updated in the forthcoming guidelines. These interim recommendations build on guidelines that have already been published in 20031 . It is important to note that these recommendations are conceptual. For practical guidance please refer to the previous guidelines and/or a technical consultant that can provide assistance in designing the survey protocol and advising on specific logistics. There are three fundamental principles of the WHO/IUATLD Global project on drug resistance surveillance. These interim recommendations follow these principles: 1. Survey sample must represent the population under study. 2. TB patients must be differentiated by previous history of treatment. 3. Laboratory results must be quality controlled. **4. Other areas of consideration (coordination, ethics, quality assurance, budget).